Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy

Head and Neck

Volumn 30, Issue 5, 2008, Pages 680-683

  Prat, Aleix ^a   Parera, Marta ^a   Reyes, Vicky ^a   Peralta, Sergio ^a   Cedrés, Susana ^a   Andreu, Jordi ^a   Huguet, Pere ^a   Del Campo, Josep Maria ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Chemotherapy; HER2; Salivary ductal carcinoma; Trastuzumab

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CERVICAL LYMPH NODE; HEAD AND NECK SURGERY; HUMAN; LOADING DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; SALIVARY GLAND DUCT CARCINOMA; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, DUCTAL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS;

EID: 43249093924     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20714     Document Type: Article

References (12)

1. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673-2678.
2. Barnes L, Everson J, Reichart P, Sidransky D. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon, France: LARC Press, 2005.
3. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997;19:126-133.
4. Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003;129:720-725.
5. Jaehne M, Roeser K, Jaekel T, Schepers J, Albert N, Löning T. Clinical and immunohistologic typing of salivary duct carcinoma. Cancer 2005;103:2526-2533.
6. Lewis J, McKinney B, Weiland L, Ferreiro J, Olsen K. Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223-230.
7. Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987;5:951-955.
8. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
9. Yu D, Hung M. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;11:6115-6121.
10. Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araujo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56:914-918.
11. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10:944-946.
12. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39:724-727.